Truist lowered the firm’s price target on Teleflex (TFX) to $200 from $227 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology.

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...

Teleflex Inc. is in discussions to acquire German medical technology firm Biotronik SE & Co.’s vascular intervention unit, according to people familiar with the matter. Teleflex is offering to ...

Teleflex (TFX) is in discussions to acquire Biotronik SE & Co.’s vascular intervention unit, offering to buy the German medical technology firm’s business for EUR 500M to EUR 1B, people ...

Teleflex is a global provider of medical technology products. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare ...

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in ...